Niagen Bioscience
NAGE
61 hedge funds and large institutions have $41.6M invested in Niagen Bioscience in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 7 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
0.04% more ownership
Funds ownership: 21.32% → 21.36% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 65 → 61 (-4)
24% less capital invested
Capital invested by funds: $54.7M → $41.6M (-$13.1M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$448K |
| 2 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$419K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$341K |
| 4 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$315K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$313K |
| 2 |
Morgan Stanley
New York
|
-$199K |
| 3 |
Barclays
London,
United Kingdom
|
-$105K |
| 4 |
LI
Leap Investments
Chicago,
Illinois
|
-$69K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$67.2K |
NAGE Hedge Fund Activity: Q1 2020 in Review
61 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2020, worth a combined $41.6M — down 24% from $54.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NAGE and 5 opened new positions — a net loss of 2 holders — while 17 trimmed existing stakes and 19 added.
The largest buyer was Vanguard Group, adding an estimated $448K. The largest seller was Tieton Capital Management, cutting an estimated $313K.
- 61 institutional investors held Niagen Bioscience (NAGE) as of Q1 2020, down from 65 in Q4 2019.
- Funds reported $41.6M of Niagen Bioscience stock for Q1 2020, down 24% quarter-over-quarter.
- 5 funds opened new Niagen Bioscience positions in Q1 2020 and 7 closed out, a net change of -2 holders.
- The largest Niagen Bioscience buyer in Q1 2020 was Vanguard Group, an estimated $448K added.
- The largest Niagen Bioscience seller in Q1 2020 was Tieton Capital Management, an estimated $313K sold.
Based on aggregated 13F filings for Q1 2020.